The reliable determination of HIV type-1 (HIV-1) levels has become an integral part of standard patient care [1] . Not only is it essential for monitoring potential antiretroviral treatment failure [2] , but also for early diagnosis as well as concerning transmission issues in serodiscordant heterosexual couples [3] . A variety of ultrasensitive molecular assays for the quantification of HIV-1 RNA levels are commercially available that differ in sensitivity, dynamic range, target region and methods of nucleic acid detection [4] . We have recently reported false-negative or underestimated viral loads in 5 out of ~170 HIV-1-infected patients that were measured with the COBAS TaqMan HIV-1 v1.0 assay (CTM v1.0; Roche Diagnostics, Mannheim, Germany), which targets the gag region, compared with HIV-1 RNA levels determined using the RealTime HIV-1 assay (Abbott RT HIV-1; Abbott Diagnostics, Wiesbaden, Germany), with primer and probe sets for detection of the integrase region [5, 6] . Sequence analyses of HIV-1 isolates from these individuals revealed that a single nucleotide mutation located in proximity to the 3´ prime end of the downstream PCR primer within the HIV-1 gag gene was responsible for the observed failures. The falsely quantitated viruses fell into four different HIV-1 subtypes. Two of them were classified as subtype B, which is most prevalent in Western Europe and North America. HIV-1 exhibits a considerable genetic diversity resulting from its high mutation rate, which has the potential to compromise the accuracy of test systems based on nucleic acid amplification technologies. Usage of primers or hybridization probes for HIV-1 real-time PCR detection located within hypervariable regions of the HIV-1 genome might result in discrepancies in quantitative measurements of viral loads obtained with different assay formats [7] [8] [9] [10] . The development of molecular diagnostic tools targeting multiple regions of the HIV-1 genome might help to improve accuracy of viral load testing in a wider range of clinically relevant HIV-1 
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Methods
Plasma samples from 160 HIV-1-infected individuals with various viral load levels recruited from the HIV outpatient clinic in Salzburg, Austria, were collected and stored below -30°C until testing. Individuals provided informed consent and the study was performed according to the Helsinki Declaration. Patients coinfected with HIV type-2 were excluded. Our study comprised problematic specimens from three individuals that were undetectable and specimens from four individuals that were significantly underestimated by the CTM v1.0 assay in comparison with the Abbott RT HIV-1 assay. Additional samples, which were all measured with the Abbott RT HIV-1 assay, were included from HIV-1-infected individuals with viral loads >1,000 copies/ml (n=50), individuals with viral loads ranging from 40 to 1,000 copies/ml (n=20) and from individuals with HIV-1 RNA levels <40 copies/ml (n=83). For the CTM v1.0 and the CTM v2.0 assays, automated RNA extraction was performed using the COBAS Ampliprep system (Roche Molecular Systems, Inc, Branchburg, NJ, USA). The Abbott m24sp automated sample preparation system (Abbott Diagnostics) was used for RNA isolation for the Abbott RT HIV-1 assay. PCR amplification was then performed either on the COBAS TaqMan 48 system (Roche Diagnostics) using the CTM v1.0 or CTM v2.0 assays with a dynamic range from 40 to 10,000,000 or 20 to 10,000,000, respectively, or on the m2000rt RealTime PCR system (Abbott Diagnostics) using the Abbott RT HIV-1 assay with a dynamic range from 40 to 10,000,000. Determination of the viral subtype was performed using the Trugene ® HIV-1 Genotyping Kit and the OpenGene ® DNA sequencing system (Siemens Medical Solutions Diagnostics, Eschborn, Germany). Viral subtypes were determined by sequence alignment using the REGA HIV-1 & 2 Automated Subtyping Tool version 2.0 [11] 
Results
We first examined plasma samples obtained from three HIV-1 infected individuals that tested negative with the CTM v1.0 assay, but were found to have significantly increased viral loads (>2,500 to >195,000 copies/ml) with the Abbott RT HIV-1 assay (Table 1 ; patients 1-3). Two were classified as 'target detected but below the limit of quantification' and one was classified as 'target not detected (TND)'. Results were confirmed with independent measurements after consecutive visits to the HIV outpatient clinic. Importantly all samples tested positive with the new CTM v2.0 assay and showed similar HIV-1 RNA levels in comparison with the Abbott RT HIV-1 assay. Furthermore, HIV-1 viral loads were significantly underestimated (6-188-fold) in plasma samples from four additional HIV-1-infected patients that were measured with the CTM v1.0, but showed comparable results with the Abbott RT HIV-1 and the CTM v2.0 assay (Table 1 ; Patients 4-7).
We then compared HIV-1 RNA levels measured with the Abbott RT HIV-1 and the CTM v1.0 assay in plasma specimens from 78 patients showing detectable viral loads with at least one assay ( Figure 1A) . The observed correlation for 64 samples quantified within the dynamic range of both assays was 0.9379 with a slope of 0.9809. Viral loads were within 0.5 log 10 copies/ml in 54 samples (84%). A total of 94% of the samples with HIV-1 RNA levels >100 copies/ml that were measured by the CTM v1.0 assay were also found positive with the Abbott RT HIV-1 assay, whereas the concordance between the two assays in samples ranging from 40-100 copies/ml was poor. HIV-1 viral loads determined with the Abbott RT HIV-1 and the CTM v2.0 were compared in plasma specimens from 73 patients exhibiting detectable viral loads with at least one assay ( Figure 1B) . Of the six samples with a viral load ranging between 40 and 100 copies/ml that were measured by the Abbott RT HIV-1 assay, five were found positive and one was found positive but below 20 copies/ml with the CTM v2.0 assay. All samples with HIV-1 RNA concentrations >100 copies/ml that were measured by the Abbott RT HIV-1 assay (n=63), tested positive with the CTM v2.0 assay. For the 67 samples quantified within the dynamic range of both assays, the observed correlation was 0.9685 with a slope of 1.0603 and viral loads ranged within 0.5 log 10 copies/ml in 61 samples (91%).
We also addressed the question of increased frequencies of detectable plasma HIV-1 RNA levels with the CTM assay in comparison with the Abbott RT HIV-1 assay as reported previously [12, 13] . Of 83 samples with HIV-1 RNA levels <40 copies/ml that were determined with the Abbott RT HIV-1 assay, five had detectable viral loads (>40 copies/ml) only with the CTM v1.0 assay, two had detectable levels only with the CTM v2.0 assay (>20 copies/ml) and four had detectable viral loads with both CTM assays ( Table 2) . 
Discussion
We evaluated the novel Roche CTM v2.0 assay in comparison with the Abbott RT HIV-1 and the Roche CTM v1.0 assays for the determination of viral loads in HIV-1-infected individuals, including specimens from individuals that were false-negative or underestimated with the CTM v1.0. Despite the general agreement of all three assays over a wide dynamic range, the CTM v2.0 assay provides a significant advantage over the CTM v1.0 assay because it allows the accurate determination of HIV-1 RNA levels in viral isolates harbouring mutations in the gag region, which is known to compromise viral load detection based on the CTM v1.0 assay. Multiplex real-time PCR approaches have the potential to improve monitoring and diagnosis of viral infections, especially for viruses harbouring a high degree of genetic variability such as HIV-1 [14] . However, additional studies in larger populations are needed to robustly assess the analytical performance of the novel CTM v2.0 assay. Several specimens from HIV-1-infected patients on highly active antiretroviral therapy, which were undetectable with the Abbott RT HIV-1 assay (<40 copies/ ml), tested positive with the CTM v2.0 assay (7%). This might reflect, at least in part, the higher sensitivity of the multiplex PCR approach and the lower detection limit of the CTM v2.0 assay (<20 copies/ml). Nevertheless, usage of the same fluorescent dye (FAM) for labelling of both TaqMan probes, directed against the long terminal repeat and the gag region, might have an additive effect that could also contribute to the higher number of detectable viral loads. An increased frequency of individuals with detectable HIV-1 RNA levels has also been described for the CTM v1.0 in comparison with the Abbott RT HIV-1 [12, 13] and the Roche COBAS Amplicor assay previously [15, 16] . The clinical significance of this phenomenon remains uncertain. Several studies indicated that episodes of low-level viraemia, as detected with the CTM v1.0 assay, did not result in the development of new resistance mutations or failure of highly active antiretroviral therapy regimens [17, 18] . However, virological follow-up should be based on results from the same assay and low-level viraemia, detected using the CTM v2.0 assay, should be interpreted with caution until a full clinical validation of this assay is available. In the face of severe consequences for therapeutic decisions and patient counselling, it is conceivable that the development of real-time PCR assays based on multiple target regions might prove as an essential step towards quality and validity in HIV-1 load testing. 
